147 related articles for article (PubMed ID: 35075986)
1. RNA-binding proteins as drivers of AML and novel therapeutic targets.
Qin T; Cheng Y; Wang X
Leuk Lymphoma; 2022 May; 63(5):1045-1057. PubMed ID: 35075986
[TBL] [Abstract][Full Text] [Related]
2. YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner.
Feng M; Xie X; Han G; Zhang T; Li Y; Li Y; Yin R; Wang Q; Zhang T; Wang P; Hu J; Cheng Y; Gao Z; Wang J; Chang J; Cui M; Gao K; Chai J; Liu W; Guo C; Li S; Liu L; Zhou F; Chen J; Zhang H
Blood; 2021 Jul; 138(1):71-85. PubMed ID: 33763698
[TBL] [Abstract][Full Text] [Related]
3. RNA-binding proteins in hematopoiesis and hematological malignancy.
Hodson DJ; Screen M; Turner M
Blood; 2019 May; 133(22):2365-2373. PubMed ID: 30967369
[TBL] [Abstract][Full Text] [Related]
4. Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.
Wang E; Lu SX; Pastore A; Chen X; Imig J; Chun-Wei Lee S; Hockemeyer K; Ghebrechristos YE; Yoshimi A; Inoue D; Ki M; Cho H; Bitner L; Kloetgen A; Lin KT; Uehara T; Owa T; Tibes R; Krainer AR; Abdel-Wahab O; Aifantis I
Cancer Cell; 2019 Mar; 35(3):369-384.e7. PubMed ID: 30799057
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target.
Vujovic A; de Rooij L; Chahi AK; Chen HT; Yee BA; Loganathan SK; Liu L; Chan DCH; Tajik A; Tsao E; Moreira S; Joshi P; Xu J; Wong N; Balde Z; Jahangiri S; Zandi S; Aigner S; Dick JE; Minden MD; Schramek D; Yeo GW; Hope KJ
Blood Cancer Discov; 2023 May; 4(3):180-207. PubMed ID: 36763002
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.
De Luca L; Trino S; Laurenzana I; Tagliaferri D; Falco G; Grieco V; Bianchino G; Nozza F; Campia V; D'Alessio F; La Rocca F; Caivano A; Villani O; Cilloni D; Musto P; Del Vecchio L
Cell Death Dis; 2017 Jun; 8(6):e2849. PubMed ID: 28569789
[TBL] [Abstract][Full Text] [Related]
7. Distinct noncoding RNAs and RNA binding proteins associated with high-risk pediatric and adult acute myeloid leukemias detected by regulatory network analysis.
Liu Z; Spiegelman VS; Wang HG
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1592. PubMed ID: 34862757
[TBL] [Abstract][Full Text] [Related]
8. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.
Vu LP; Prieto C; Amin EM; Chhangawala S; Krivtsov A; Calvo-Vidal MN; Chou T; Chow A; Minuesa G; Park SM; Barlowe TS; Taggart J; Tivnan P; Deering RP; Chu LP; Kwon JA; Meydan C; Perales-Paton J; Arshi A; Gönen M; Famulare C; Patel M; Paietta E; Tallman MS; Lu Y; Glass J; Garret-Bakelman FE; Melnick A; Levine R; Al-Shahrour F; Järås M; Hacohen N; Hwang A; Garippa R; Lengner CJ; Armstrong SA; Cerchietti L; Cowley GS; Root D; Doench J; Leslie C; Ebert BL; Kharas MG
Nat Genet; 2017 Jun; 49(6):866-875. PubMed ID: 28436985
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic Analysis Identifies RNA Binding Proteins as Putative Regulators of Myelopoiesis and Leukemia.
Saha S; Murmu KC; Biswas M; Chakraborty S; Basu J; Madhulika S; Kolapalli SP; Chauhan S; Sengupta A; Prasad P
Front Oncol; 2019; 9():692. PubMed ID: 31448224
[TBL] [Abstract][Full Text] [Related]
10. Loss of RNA-binding protein CELF2 promotes acute leukemia development via FAT10-mTORC1.
Guo T; Wang Y; Sun X; Hou S; Lan Y; Yuan S; Yang S; Zhao F; Chu Y; Ma Y; Cheng T; Yu J; Liu B; Yuan W; Wang X
Oncogene; 2024 May; 43(19):1476-1487. PubMed ID: 38514854
[TBL] [Abstract][Full Text] [Related]
11. The m
Weng H; Huang F; Yu Z; Chen Z; Prince E; Kang Y; Zhou K; Li W; Hu J; Fu C; Aziz T; Li H; Li J; Yang Y; Han L; Zhang S; Ma Y; Sun M; Wu H; Zhang Z; Wunderlich M; Robinson S; Braas D; Hoeve JT; Zhang B; Marcucci G; Mulloy JC; Zhou K; Tao HF; Deng X; Horne D; Wei M; Huang H; Chen J
Cancer Cell; 2022 Dec; 40(12):1566-1582.e10. PubMed ID: 36306790
[TBL] [Abstract][Full Text] [Related]
12. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets.
Su R; Lin HS; Zhang XH; Yin XL; Ning HM; Liu B; Zhai PF; Gong JN; Shen C; Song L; Chen J; Wang F; Zhao HL; Ma YN; Yu J; Zhang JW
Oncogene; 2015 Jun; 34(25):3226-39. PubMed ID: 25174404
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.
Zhou J; Bi C; Ching YQ; Chooi JY; Lu X; Quah JY; Toh SH; Chan ZL; Tan TZ; Chong PS; Chng WJ
J Hematol Oncol; 2017 Jul; 10(1):138. PubMed ID: 28693523
[TBL] [Abstract][Full Text] [Related]
14. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
Schneider E; Pochert N; Ruess C; MacPhee L; Escano L; Miller C; Krowiorz K; Delsing Malmberg E; Heravi-Moussavi A; Lorzadeh A; Ashouri A; Grasedieck S; Sperb N; Kumar Kopparapu P; Iben S; Staffas A; Xiang P; Rösler R; Kanduri M; Larsson E; Fogelstrand L; Döhner H; Döhner K; Wiese S; Hirst M; Keith Humphries R; Palmqvist L; Kuchenbauer F; Rouhi A
Leukemia; 2020 May; 34(5):1253-1265. PubMed ID: 31768018
[TBL] [Abstract][Full Text] [Related]
16. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.
Kvinlaug BT; Chan WI; Bullinger L; Ramaswami M; Sears C; Foster D; Lazic SE; Okabe R; Benner A; Lee BH; De Silva I; Valk PJ; Delwel R; Armstrong SA; Döhner H; Gilliland DG; Huntly BJ
Cancer Res; 2011 Jun; 71(12):4117-29. PubMed ID: 21505102
[TBL] [Abstract][Full Text] [Related]
17. OncomiR or antioncomiR: Role of miRNAs in Acute Myeloid Leukemia.
He C; Luo B; Jiang N; Liang Y; He Y; Zeng J; Liu J; Zheng X
Leuk Lymphoma; 2019 Feb; 60(2):284-294. PubMed ID: 30187809
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs: pivotal regulators in acute myeloid leukemia.
Li M; Cui X; Guan H
Ann Hematol; 2020 Mar; 99(3):399-412. PubMed ID: 31932900
[TBL] [Abstract][Full Text] [Related]
19. In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.
Abdul-Nabi AM; Yassin ER; Varghese N; Deshmukh H; Yaseen NR
PLoS One; 2010 Aug; 5(8):e12464. PubMed ID: 20805992
[TBL] [Abstract][Full Text] [Related]
20. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
